Inogen, Inc. (INGN)
$5.22
Rating:
Recommendation:
Buy
| Symbol | INGN |
|---|---|
| Price | $5.22 |
| Beta | 0.986 |
| Volume Avg. | 0.28M |
| Market Cap | 121.075M |
| Shares () | - |
| 52 Week Range | 5.055-26.11 |
| 1y Target Est | - |
| DCF Unlevered | INGN DCF -> | |
|---|---|---|
| DCF Levered | INGN LDCF -> | |
| ROE | -31.98% | Strong Sell |
| ROA | -25.72% | Sell |
| Operating Margin | - | |
| Debt / Equity | 7.96% | Neutral |
| P/E | -1.23 | Sell |
| P/B | 0.44 | Neutral |
Latest INGN news
About
Download (Excel)Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.